lobbying_activities: 3246660

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3246660	fccb5bfc-5fac-4857-b945-60cb1aa10cd2	Q3	ERVIN GRAVES STRATEGY GROUP, LLC	13836	EMERGENT BIOSOLUTIONS INC.	2024	third_quarter	DIS	Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25; Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines; NDAA for Fiscal Year 2025 - provisions related to biological and chemical defense and access to naloxone; FAA reauthorization - increasing access to naloxone.	HOUSE OF REPRESENTATIVES,SENATE	50000		0	0	2024-10-17T23:45:52-04:00